XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):
| 2021 |  | 2020 |  | 2019
Net revenue: |  |  |  |  |
Clinical Services | $ | 404,172 |  |  | $ | 382,337 |  |  | $ | 361,161 |
Pharma Services | 80,157 |  |  | 62,111 |  |  | 47,669 |
Total net revenue | 484,329 |  |  | 444,448 |  |  | 408,830 |
Cost of revenue: |  |  |  |  |
Clinical Services(1) | 244,360 |  |  | 215,529 |  |  | 185,612 |
Pharma Services(2) | 52,909 |  |  | 43,026 |  |  | 26,382 |
Total cost of revenue | 297,269 |  |  | 258,555 |  |  | 211,994 |
Gross profit: |  |  |  |  |
Clinical Services | 159,812 |  |  | 166,808 |  |  | 175,549 |
Pharma Services | 27,248 |  |  | 19,085 |  |  | 21,287 |
Total gross profit | 187,060 |  |  | 185,893 |  |  | 196,836 |
Operating expenses: |  |  |  |  |
General and administrative | 221,347 |  |  | 143,794 |  |  | 127,993 |
Research and development | 21,873 |  |  | 8,229 |  |  | 8,487 |
Sales and marketing | 62,594 |  |  | 47,862 |  |  | 47,350 |
Total operating expenses | 305,814 |  |  | 199,885 |  |  | 183,830 |
(Loss) income from operations | (118,754) |  |  | (13,992) |  |  | 13,006 |
Interest expense, net | 5,082 |  |  | 7,019 |  |  | 3,713 |
Other expense (income), net | 499 |  |  | (7,906) |  |  | 4,630 |
Gain on investment in and loan receivable from non-consolidated affiliate, net | (109,260) |  |  | (3,955) |  |  | — |
Loss on extinguishment of debt | — |  |  | 1,400 |  |  | 1,018 |
Loss on termination of cash flow hedge | — |  |  | 3,506 |  |  | — |
(Loss) income before taxes | (15,075) |  |  | (14,056) |  |  | 3,645 |
Income tax benefit | (6,728) |  |  | (18,228) |  |  | (4,361) |
Net (loss) income | $ | (8,347) |  |  | $ | 4,172 |  |  | $ | 8,006 |
(1) Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory. (2) Pharma Services cost of revenue in 2021 includes $1.2 million of amortization of acquired Inivata developed technology intangible assets.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration